Menopausal osteoporosis: screening, prevention and treatment

Singapore Med J. 2021 Apr;62(4):159-166. doi: 10.11622/smedj.2021036.

Abstract

Screening for osteoporosis in women can be based on age and weight, using the Osteoporosis Screening Tool for Asians and assessment for other risk factors such as early menopause, Chinese ethnicity and other secondary factors. Based on the resulting risk profile, women can be triaged to dual-energy X-ray absorptiometry (DEXA) scanning for definite diagnosis of osteoporosis. Treatment should be considered in women with previous fragility fractures, DEXA-diagnosed osteoporosis and high risk of fracture. Exercise improves muscle function, can help prevent falls and has moderate effects on improvements in bone mass. Women should ensure adequate calcium intake and vitamin D. Menopausal hormone therapy (MHT) effectively prevents osteoporosis and fractures, and should be encouraged in those aged < 50 years. For women aged < 60 years, MHT or tibolone can be considered, especially if they have vasomotor or genitourinary symptoms. Risedronate or bisphosphonates may then be reserved for those aged over 60 years.

Keywords: menopause; osteoporosis; prevention; screening; treatment.

MeSH terms

  • Bone Density
  • Diphosphonates
  • Female
  • Humans
  • Menopause
  • Osteoporosis* / diagnosis
  • Osteoporosis* / prevention & control
  • Osteoporosis, Postmenopausal* / diagnosis
  • Osteoporosis, Postmenopausal* / prevention & control

Substances

  • Diphosphonates